| J9271 | Injection, pembrolizumab, 1 mg | 13,000 | $40 | $559K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 4,470 | $30 | $147.5K |
| J0897 | Injection, denosumab, 1 mg | 3,840 | $20 | $69.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 670 | $90 | $61.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 190 | $130 | $25.5K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12,100 | $1 | $24.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 230 | $100 | $24.1K |
| 86300 | The lab analyst performs a quantitative test to evaluate the patient’s serum for the cancer tumor antigen CA 15 3, a tumor marker for breast cancer, and a similar marker called CA 27.29. | 580 | $20 | $11.6K |
| 82378 | The lab analyst performs the technical lab test to analyze the quantity of carcinoembryonic antigen, or CEA, in the blood or other bodily fluid. Most commonly clinicians order a CEA test to monitor… | 640 | $20 | $11.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 180 | $60 | $10K |